MS K.K.

MSD K.K. is the Japanese subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and stands as one of the largest research-driven pharmaceutical companies in Japan. The company was established in its current form in 2010 following the merger of Banyu Pharmaceutical and Schering-Plough, inheriting a legacy of medical innovation in the region dating back over a century. MSD K.K. focuses on four primary therapeutic areas: Oncology, Vaccines, Infectious Diseases, and Specialty Care, including Diabetes and Cardiovascular health. Its flagship product, Keytruda (pembrolizumab), has revolutionized cancer treatment in Japan across multiple indications, supported by a robust local clinical development engine. The company operates a significant manufacturing facility in Shizuoka and maintains extensive partnerships with local firms like Eisai to expand its footprint in the Japanese healthcare ecosystem.